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Background: CYFRA 21-1 (cytokeratin 19 fragment) and C-reactive proteins (CRP) were separately reported to be
associated with prognosis of head and neck squamous cell carcinoma. The combined roles of CYFRA 21-1 and CRP
levels were rarely investigated in oral squamous cell carcinoma (OSCC). The purpose of the present study was to
analyze the relationship between preoperative levels of both CYFRA 21-1 and CRP, with clinicopathological factors
and prognosis in OSCC patients.
Methods: A retrospective study was performed on 130 OSCC patients between December 2010 and June 2013.
Their serum CYFRA 21-1 and CRP levels were measured preoperatively.
Results: CYFRA 21-1 level of ≥3.3 ng/mL and CRP level of ≥5.0 mg/L were significantly associated with pathological
tumor status (P < 0.001), tumor depth (>10 vs. ≤10 mm, P = 0.001), bone invasion (P = 0.001), skin invasion (P = 0.006),
pathologic nodal metastasis (P = 0.012), and disease-free survival (P = 0.009). Higher CYPFRA 21-1 and CRP levels were
also associated with higher risks of distant metastasis (log-rank test, P = 0.013, (HR [95 % CI]) 1.692 [1.097–2.414]).
Conclusions: Preoperative CYFRA 21-1 and CRP levels are probable candidates as biomarkers for risk stratification in
OSCC.Background
Oral cavity cancer is one of the commonest cancers in
the world but shows wide geographical variation due to
habitual consumption of cigarette, alcohol, and areca
quid (AQ). The incidence of oral cavity cancer ranks
fifth among the types of cancer in Taiwan [1]. Search for
significant biomarkers predicting tumor behaviors and
patients’ prognosis may help clinicians choose appropri-
ate treatment for those patients [2–7]. Newer markers
that can help us better and more precisely predict pa-
tients’ prognosis are needed clinically.
In oral squamous cell carcinoma (OSCC), to early de-
tect tumor, it usually links to the squamous cell compo-
nent of cancer. Cytokeratins are structural proteins
forming the subunits of epithelial intermediary filaments.
In the literature, 20 different cytokeratin polypeptides* Correspondence: bigmac@adm.cgmh.org.tw
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mal and benign epithelial cells and various carcinomas,
particularly the lung cancer. CYFRA 21-1 is the serum
soluble fragment of cytokeratin 19 and was first de-
scribed in the mid 1990s [8]. Increased concentration of
CYFRA 21-1 was shown to be associated with poorer
prognosis in patients with lung cancer [9, 10]. The meas-
urement of CYFRA 21-1 in patients with squamous cell
carcinoma of the head and neck (HNSCC) is also an estab-
lished tumor marker and prognosticator [8, 11–17].
CYFRA 21-1 serum levels are significantly higher in pa-
tients with HNSCC compared to a healthy or control group
[8]. Sawant et al. [18] reported a sensitivity of 84 % and a
specificity of 93 % of CYFRA 21-1 in patients with oropha-
ryngeal cancer. They found the serum marker reduced sig-
nificantly after surgical therapy of the primary tumor.
A second potentially significant marker is the acute
phase protein CRP, which has also been shown to correlate
with survival in human cancers [3, 19–22]. We previously
demonstrated that C-reactive protein (CRP) elevation in
OSCC is associated with poor survival and tumor invasive-
ness [2, 3]. Elevated CRP could be a marker for chronicis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characteristics of the 130 oral cavity squamous cell
carcinoma patients







Site of primary tumor
Tongue 58 (44.6)
Mouth floor 3 (2.3)
Lip 5 (3.8)
Buccal mucosa 44 (33.8)
Alveolar ridge 13 (10.0)
Hard palate 0 (0)













Stage I 28 (21.5)
Stage II 17 (13.1)
Stage III 23 (17.7)
Stage IV 62 (47.7)
Treatment
Surgery alone 57 (43.8)
Surgery with adjuvant radiation therapy 12 (9.2)
Surgery with adjuvant chemoradiation therapy 58 (44.6)
Chemoradiation therapy plus surgery 3 (2.3)
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chronic inflammation itself also acts as a stimulus for
angiogenesis, cell proliferation, and tumorigenesis [23–25].
However, the relationship between CYFRA 21-1 and CRP,
and their potential combined value as prognostic markers
of survival, has not been previously explored in OSCC. In
this study, we retrospectively analyzed 130 OSCC patients
who were primarily treated with radical excision in our in-
stitution. The aim of this study was to evaluate the import-
ance of CYFRA 21-1 and CRP as tumor markers in
patients with OSCC at the time of initial diagnosis in cor-
relation with tumor size, histologic grading, and lymph
node metastasis.
Methods
Patients and staging workup
We retrospectively reviewed 130 consecutive OSCC pa-
tients who had undergone primary radical surgery and
were subsequently followed at Chang Gung Memorial
Hospital from December 2010 to June 2013. The serum
samples were obtained prior to surgery. All patients
underwent radical surgery with curative intent. The
follow-up for each patient began at the time of cancer
treatment and ended at the time of death or last time
clinic follow-up, whichever came first.
The patients in this series underwent an extensive pre-
operative survey, which included a detailed medical his-
tory and a complete physical examination, and computed
tomography (CT) or magnetic resonance imaging (MRI)
scans of the head and neck. Abdominal sonography and
bone scan or positron emission tomography (PET) were
also included in preoperative tumor survey. The guide-
lines of the 2010 American Joint Committee on Cancer
(AJCC) (tumor-node-metastasis (TNM) classification)
were employed for clinical staging [26]. Patients who were
initially diagnosed of a distant metastasis were excluded
from the analysis.
Treatment
One hundred twenty-seven participants underwent a
wide excision of the primary tumors with 1-cm safe
margins (both peripheral and deep margins), which
were cryosectioned to ensure that the margin was free
from the tumor tissue. Supraomohyoid or modified
radical neck dissection was performed according to
patients’ clinical nodal status. All histological parame-
ters including the depth of infiltration, bone, skin in-
vasion, lymph node extracapsular spread (ECS), and
grade of differentiation were recorded.
Postoperative radiotherapy (RT) was performed in pa-
tients who presented a stage pT4 tumor, pathologically
positive lymph nodes, or pathologically close margins
(≤4 mm). Concomitant chemoradiotherapy (CCRT) with
cisplatin-based agents was administered to patients withECS or pathological multiple lymph node metastases
[27, 28]. Three patients received CCRT first, and re-
ceived salvage radical surgery due to persistence of
disease.
Follow-up
All of the patients had a checkup every month during
the first 6 months after treatment, every 2 months dur-
ing the following 6 months, every 3 months during the
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tients were subjected to a hemogram, blood chemistry,
chest X-ray, and CT scan or MRI in the first 3 and
6 months and then annually afterward. Patients with ab-
normal clinical symptoms/signs or laboratory data dur-
ing follow-up would receive a bone scan and liver
ultrasound.
Measurement of CYFRA 21-1
Cytokeratin 19 fragments were detected by the monoclonal
antibodies KS 19.1 and BM 19.21; these antibodies are
specific for two different epitopes of cytokeratin 19 [29].
The measurement of CYFRA 21-1 was completed inTable 2 The associations between preoperative CRP, CYFRA 21-1, an
CRP
Negative (n (%)) Positive (n (%)
Pathologic tumor status
Earlya (n = 74) 64 (86.5) 10 (13.5)
Advancedb (n = 56) 29 (51.8) 27 (48.2)
Pathologic N stage
N0 (n = 68) 54 (79.4) 14 (20.6)
N1 (n = 25) 18 (72.0) 7 (28.0)
N2 (n = 37) 21 (56.8) 16 (43.2)
Nodal status
(−) metastasis, (−) ECS (n = 68) 54 (79.4) 14 (20.6)
(+) metastasis, (−) ECS (n = 23) 18 (78.3) 5 (21.7)
(+) metastasis, (+) ECS (n = 39) 21 (53.8) 18 (46.2)
Differentiation
Well (n = 32) 21 (65.6) 11 (34.4)
Moderate (n = 80) 61 (76.2) 19 (23.8)
Poor (n = 18) 11 (61.1) 7 (38.9)
Tumor stage
Earlyc (n = 45) 40 (88.9) 5 (11.1)
Advancedd (n = 85) 53 (62.4) 32 (37.6)
Skin invasion
No (n = 117) 88 (75.2) 29 (24.8)
Yes (n = 13) 5 (38.5) 8 (61.5)
Bone invasion
No (n = 105) 83 (79.0) 22 (21.0)
Yes (n = 25) 10 (40.0) 15 (60.0)
Tumor depth ≥10 mm
No (n = 60) 53 (88.3) 7 (11.7)






eFisher’s exact testelectrochemiluminescent immunoassay (ECLIA) using the
CYFRA 21-1 reagent kit. The CYFRA 21-1 concentration
of each sample was automatically calculated in a Roche
Analytics E170 immunology analyzer. The calculated con-
centration of CYFRA 21-1 was expressed in ng/mL, and
the cut-off level of 3.3 ng/mL was used according to the
manufacturer’s instructions (Roche Diagnostics, Mannheim,
Germany) [30]. CYFRA 21-1 serum levels were determined
for each patient at the time of initial diagnosis.
Measurement of CRP
Preoperative serum CRP levels were checked at the time
of tissue diagnosis before any medical intervention ord clinicopathologic parameters (N = 130)
CYFRA 21-1
) P value Negative (n (%)) Positive (n (%)) P value
<0.001e 66 (89.2) 8 (10.8) 0.308
46 (82.1) 10 (17.9)
0.049 59 (86.8) 9 (13.2) 0.024
25 (100.0) 0 (0.0)
28 (75.7) 9 (24.3)
0.014 59 (86.8) 9 (13.2) 0.039
23 (100.0) 0 (0.0)
30 (76.9) 9 (23.1)
0.304 29 (90.6) 3 (9.4) 0.689
68 (85.0) 12 (15.0)
15 (83.3) 3 (16.7)
0.002e 38 (84.4) 7 (15.6) 0.791e
74 (87.1) 11 (12.9)
0.009e 102 (87.2) 15 (12.8) 0.389e
10 (76.9) 3 (23.1)
<0.001e 91 (86.7) 14 (13.3) 0.750e
21 (84.0) 4 (16.0)
<0.001e 54 (90.0) 6 (10.0) 0.311e
58 (82.9) 12 (17.1)
Fig. 1 Survival curves in 130 OSCC patients related to the preoperative CRP level. a The lower CRP group (<5.0 mg/L) showed significantly better
DFS compared to the higher CRP level group (≥5.0 mg/L) (P = 0.012). b The lower CRP group showed significantly better OS compared to the
higher CRP level group (P = 0.021)
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ences. A fresh blood sample was collected and sent to
the laboratory for testing. Serum CRP levels were de-
tected using an auto-analyzer (Hitachi 7600-210, Hitachi
Medico, Tokyo). The cut-off point for serum CRP was
set at 5.0 mg/L, which is internationally adopted for in-
flammation [3, 5, 31].
Ethics
The study was approved by the Institutional Review Board




Table 1 shows the clinicopathological characteristics of
the 130 OSCC patients (114 males and 16 females). The
tongue (N = 58, 44.6 %) and the buccal mucosa (N = 44,Fig. 2 Survival curves in 130 OSCC patients related to the preoperative CYF
DFS compared to the higher CYFRA 21-1 level group (≥3.3 ng/mL) (P = 0.1
the higher CYFRA 21-1 level group (P = 0.665)33.8 %) were the most common primary tumor sites. The
tumor stage distribution was 28 (21.5 %) in stage I, 17
(13.1 %) in stage II, 23 (17.7 %) in stage III, and 62
(47.7 %) in stage IV. The median follow-up period was
19.0 months. All patients received radical surgeries, and
the adjuvant therapies were listed in Table 1. All patients
were followed in clinic at least 6 months after treatment.
CRP levels, clinicopathological variables, and prognosis
Elevated CRP levels (CRP ≥5.0 mg/L) were found to be as-
sociated with the skin invasion (P = 0.009), bone invasion
(P < 0.001), tumor depth (≥10 vs. <10 mm, P < 0.001),
pathological tumor status (P < 0.001), and pathologic nodal
metastasis (P = 0.049) (Table 2). Higher CRP level was also
found to be related with lymph node metastasis with ECS
(P = 0.014).
When comparing the survival differences between the
higher CRP group (CRP ≥5.0 mg/L) and lower CRPRA 21-1. a The lower CYFRA 21-1 group (<3.3 ng/mL) showed better
24). b The lower CYFRA 21-1 group showed similar OS compared to
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was significantly better in the latter than that of the
former group (log-rank test, P < 0.012, Fig. 1a). In
addition, in the higher CRP group (CRP ≥5.0 mg/L), the
overall survival (OS) was also remarkably worse than
that in the lower CRP group (CRP <5.0 mg/L) (log-rank
test, P = 0.021, Fig. 1b).
CYFRA 21-1 level and its relation with clinicopathological
variables and prognosis
A higher CYFRA 21-1 level (CYFRA 21-1 ≥3.3 ng/mL) was
statistically related with pathological nodal status (P =
0.024) and nodal ECS (P = 0.039). However, elevatedTable 3 The associations between preoperative CRP, CYFRA 21-1, an
CRP (−), CYFRA 21-1 (−) CRP (−),CYFRA
(n (%)) (n (%
Tumor stage
Earlya (n = 45) 33 (73.3) 7 (15.
Advancedb (n = 85) 52 (61.2) 1 (1.
Pathologic N stage
N0 (n = 68) 47 (69.1) 7 (10.
N1 (n = 25) 18 (72.0) 0 (0.
N2 (n = 37) 20 (54.1) 1 (2.
Nodal status
(−) metastasis, (−) ECS (n = 68) 47 (69.1) 7 (10.
(+) metastasis, (−) ECS (n = 23) 18 (78.3) 0 (0.
(+) metastasis, (+) ECS (n = 39) 20 (51.3) 1 (2.
Differentiation
Well (n = 32) 20 (62.5) 1 (3.
Moderate (n = 80) 55 (68.8) 6 (7.
Poor (n = 18) 10 (55.6) 1 (5.
Pathologic tumor status
Earlyc (n = 74) 56 (75.7) 8 (10.
Advancedd (n = 56) 29 (51.8) 0 (0.
Skin invasion
No (n = 117) 80 (68.4) 8 (6.
Yes (n = 13) 5 (38.5) 0 (0.
Bone invasion
No (n = 105) 75 (71.4) 8 (7.
Yes (n = 25) 10 (40.0) 0 (0.
Tumor depth ≥10 mm
No (n = 60) 47 (78.3) 6 (10.
Yes (n = 70) 38 (54.3) 2 (2.






eFisher’s exact testCYFRA 21-1 level was not related with bone invasion,
skin invasion, and tumor depth (Table 2).
The DFS was insignificantly worse in the higher
CYFRA 21-1 level group (CYFRA 21-1 ≥ .3 ng/mL) than
that of the lower CYFRA 21-1 level group (CYFRA
21-1 <3.3 ng/mL) (log-rank test, P = 0.124, Fig. 2a). In
addition, the OS was neither associated with the CYFRA
21-1 level (log-rank test, P = 0.665, Fig. 2b).
Combined CRP and CYFRA 21-1 level and its relation with
clinicopathological variables and prognosis
CRP level was related with CYFRA 21-1 level in linear
correlation (P = 0.010). A higher CYFRA 21-1 level wasd clinicopathologic parameters (N = 130)
21-1 (+) CRP (+),CYFRA 21-1 (−) CRP (+),CYFRA 21-1 (+)
)) (n (%)) (n (%)) P value
6) 5 (11.1) 0 (0.0) 0.009e
2) 22 (25.9) 10 (11.8)
3) 12 (17.6) 2 (2.9) 0.012e
0) 7 (28.0) 0 (0.0)
7) 8 (21.6) 8 (21.6)
3) 12 (17.6) 2 (2.9) 0.006e
0) 5 (21.7) 0 (0.0)
6) 10 (25.6) 8 (20.5)
1) 9 (28.1) 2 (6.2) 0.734
5) 13 (16.2) 6 (7.5)
6) 5 (27.8) 2 (11.1)
8) 10 (13.5) 0 (0.0) <0.001e
0) 17 (30.4) 10 (17.9)
8) 22 (18.8) 7 (6.0) 0.006e
0) 5 (38.5) 3 (23.1)
6) 16 (15.2) 6 (5.7) 0.001e
0) 11 (44.0) 4 (16.0)
0) 7 (11.7) 0 (0.0) <0.001e
9) 20 (28.6) 10 (14.3)
-1 <3.3 ng/mL, CYFRA 21-1 (+) CYFRA 21-1 ≥3.3 ng/mL, ECS extra-capsular
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tients were divided into four groups according to the pre-
operative higher or lower CYFRA 21-1 and CRP levels, a
close association was observed between a coexistence of
higher CYFRA 21-1 (≥3.3 ng/mL) and higher CRP
(≥5.0 mg/L) status and pathological tumor status (χ2 trend
test P < 0.001), pathologic nodal metastasis (χ2 trend
test P = 0.012), tumor stage (P = 0.009), bone invasion
(P = 0.001), skin invasion (P = 0.006), and tumor depth
(≥10 vs. <10 mm, P < 0.001) (Table 3).
When the survival rates of the four groups were com-
pared, the DFS of the higher CYFRA 21-1 and higher
CRP level group was significantly lower than that of the
other groups (log-rank test, P = 0.009, Fig. 3a). In
addition, the OS was lower in the same group than that
in the other groups (log-rank test, P = 0.098, Fig. 3b) but
does not reach statistical significance (Table 4).Discussion
Deng et al. analyzed 142 HNSCC cases, and they
found that the positive rates of CYFRA 21-1 in-
creased with progression of HNSCC; serum CYFRA
21-1 levels were related to the primary tumor status
and nodal status (N) (P < 0.001), but not related to
patient age, gender, smoking and drinking habit, or
histopathological grade (P > 0.05). The CYFRA 21-1 in
HNSCC decreased significantly (P < 0.001) after treat-
ment [30]. Doweck et al. reported that CYFRA 21-1
can be used in HNSCC at a sensitivity of 60 %, with
a good correlation with tumor stage and an inverse
correlation with the grade of tumor differentiation
[14]. They suggested that CYFRA 21-1 was a good
marker for HNSCC. In our study, CYFRA 21-1 was
not associated with bone, skin, or perineural invasion.
The only significant parameter is the lymph nodeFig. 3 Survival curves in 130 OSCC patients related to the preoperative CRP
group showed significantly better DFS compared to the higher CRP and hi
CYFRA 21-1 level group showed significantly better OS compared to the hmetastasis. It implies that CYFRA 21-1 could be re-
leased into the bloodstream by metastatic tumor cells.
Regarding the role of CYFRA 21-1 in predicting prog-
nosis, the results are positive in the literature [14, 32].
However, the prognostic role of CYFRA 21-1 in our
study was statistically insignificant. There are two pos-
sible reasons: one is low sensitivity rate of elevated
CYFRA 21-1. Eighteen patients (13.85 %) were found
with elevated CYPFRA 21-1. The other is the cut-off
values of CYFRA 21-1 in the literature are different.
The results could be different when choosing different
cut-off points. It is also apparent that there is contra-
dictory information emerging from different laborator-
ies. In Wang et al.’s review, different methods in the
detection of CYFRA 21-1 including immunoradiometric
assay, ECLIA, and enzyme-linked immunosorbent assay
(ELISA) were used in the literature [33]. The use of
CYFRA 21-1 in detecting OSCC could be limited
because the increase in CYFRA 21-1 provides low sensi-
tivity [18].
Serum CYFRA 21-1 level was linearly associated with
CRP level (P = 0.010). As seen in the results, the ele-
vated CRP was associated with bone invasion, skin in-
vasion, and lymph node metastasis. CRP was elevated
due to peri-tumor tissue destruction or lymph node
metastasis. When we combined these two markers, a
strong correlation was found between both higher
CYPFRA 21-1 and CRP levels and tumor stage, nodal
metastasis, skin invasion, and bone invasion (Table 3).
In OSCC patients with lymph node metastasis, the
serum CYPFRA 21-1 and CRP could be useful in strati-
fying the patients.
Regarding patients’ survival, simultaneous elevation of
the CYPFRA 21-1 and CRP level was related with worse
DFS and OS in univariate analysis. Another prognostic
end point is the interval between treatment and distantand CYFRA 21-1 level. a The lower CRP and lower CYFRA 21-1 level
gher CYFRA 21-1 level group (P = 0.009). b The lower CRP and lower
igher CRP and higher CYFRA 21-1 level group (P = 0.098)
Table 4 Univariate log-rank test of prognostic covariates in 130 patients with oral cavity squamous cell carcinoma regarding
disease-free and overall survival
DFS, P value OS, P value
[HR (95 % CI)] [HR (95 % CI)]
Age (years)
<50 0.251 0.885
≥50 0.678 (0.349–1.316) 0.938 (0.395–2.228)
Sex
Female 0.776 0.164
Male 1.163 (0.411–3.297) 0.490 (0.179–1.337)
Nodal status
(−) metastasis, (−) ECS 0.001 0.008
(+) metastasis, (−) ECS 1.193 (0.384–3.705) 1.858 (0.463–7.447)
(+) metastasis, (+) ECS 3.586 (1.733–7.420) 4.618 (1.729–12.338)
Differentiation
Well/moderate 0.027 0.041
Poor 2.437 (1.105–5.372) 2.868 (1.043–7.886)
Pathologic tumor status
Earlya 0.023 0.096
Advancedb 2.172 (1.111–4.247) 2.084 (0.877–4.949)
CRP
<5 mg/mL 0.016 0.027
≥5 mg/mL 2.274 (1.163–4.448) 2.636 (1.118–6.217)
Cyfra 21-1
<3.3 ng/mL 0.135 0.667
≥3.3 ng/mL 1.885 (0.821–4.328) 0.726 (0.169–3.120)
Tumor depth
<10 mm 0.030 0.052
≥10 mm 2.207 (1.080–4.510) 2.560 (0.991–6.613)
Cyfra 21-1 and CRP 0.019 0.235
Cyfra 21-1 < 3.3 ng/mL, CRP < 5 mg/L 1 1
Cyfra 21-1≥ 3.3 ng/mL, CRP < 5 mg/L 0.575 (0.077–4.300) 0.000 (0.000)
Cyfra 21-1 < 3.3 ng/mL, CRP≥ 5 mg/L 1.683 (0.761–3.722) 2.578 (1.036–6.414)
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21-1 and CRP levels carry higher risks of distant metasta-
sis (Fig. 4, log-rank test, P = 0.013, HR [95 % CI] 1.692
[1.097–2.414]). The elevation of CYPFRA 21-1 could be
from the release of tumor antigen into the blood stream.
Host immune system responds to tumor growth with ele-
vated inflammatory cytokines (such as interleukin-6) and
subsequently elevates the serum CRP levels [34]. The as-
sociation of higher CYPFRA 21-1 and CRP with distant
metastasis could be attributed to the advanced tumorstage or the existence of circulating tumor cells. Combin-
ation of these two markers provides clinicians clues of
worse prognosis in OSCCs before surgeries.
We demonstrated that elevated CYFRA 21-1 levels in
OSCC predicted nodal metastases in OSCC patients. The
present study has further demonstrated the use of com-
bined CYFRA 21-1 and CRP as a prognostic marker in
OSCC and may be significant as a biomarker to predict
prognosis and stratify patients for adjuvant therapies in
the absence of traditional indications such as lymph node
Fig. 4 Distant metastatic rates in 130 OSCC patients related to the preoperative CRP and CYFRA 21-1 level. The higher CRP and higher CYFRA
21-1 level group showed significantly higher distant metastatic rate compared to the lower CRP or lower CYFRA 21-1 level group (P = 0.013)
Hsu et al. World Journal of Surgical Oncology  (2015) 13:253 Page 8 of 9ECS. In this study, the follow-up period was relatively
short and patient number was not large. In multivariate
adjustment, the prognostic role of combined CYPFRA 21-
1 and CRP in our analysis does not reach statistical signifi-
cance. Our present study per se is preliminary. Further
work and longer follow-up are required to elucidate the
exact molecular mechanisms and clinical application of
CYFRA 21-1 and CRP in OSCC.
Conclusions
Preoperative CYFRA 21-1 serum concentration was re-
lated with lymph node metastasis. CRP level predicts
greater extent of tumor destruction including bone inva-
sion, skin invasion, tumor status, and lymph node metas-
tasis. Combining the CYPFRA 21-1 and CRP levels
predicts higher risks of disease recurrence and distant me-
tastasis. Preoperative CYFRA 21-1 and CRP levels are thus
probable candidates as biomarkers for risk stratification in
OSCC.
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